The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Yesafili, an aflibercept biosimilar, according to a press release from Biocon Biologics.
Yesafili is intended to treat wet age-related macular degeneration and visual impairment due to macular edema secondary to retinal vein occlusion, diabetic macular edema or myopic choroidal neovascularization.
Data show that Yesafili has comparable quality, safety and efficacy to the reference product Eylea (aflibercept, Regeneron), the release said.
“This is further confirmation of our strong